ClinConnect ClinConnect Logo
Search / Trial NCT07041567

İn This Study, Patients Undergoing Bariatric Surgery Will be Divided Into Two Groups. The Control Group Will Receive Normal-flow, While the Study Group Will Receive Low-flow Inhalational Anesthesia. The Aim is to Compare the Incidence of Postop Atelectasis-between the Two Groups Using USG Evaluation

Launched by ISTANBUL UNIVERSITY · Jun 26, 2025

Trial Information

Current as of July 21, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how different types of anesthesia—specifically low-flow versus normal-flow inhalational anesthesia—affect the development of lung problems called atelectasis after weight-loss surgery (bariatric surgery). Atelectasis means parts of the lungs don’t fully expand, which can make breathing harder after surgery. To find out which anesthesia method is better, doctors will use painless and safe lung ultrasounds (a type of scan) and breathing tests before and after the surgery to check lung health.

If you are between 18 and 65 years old, scheduled for a specific type of weight-loss surgery called sleeve gastrectomy, and have a certain level of overall health (ASA III), you might be eligible to join. People with serious lung diseases, uncontrolled high blood pressure or diabetes, or other major health problems won’t be able to participate. The study involves no extra risks beyond the usual surgery and care, and no invasive procedures will be done. This trial will help doctors understand the best anesthesia approach to reduce lung complications after bariatric surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Will undergo Sleeve Gastrectomy surgery;
  • 18-65 years old
  • ASA III patients.
  • Exclusion Criteria:
  • Patients who do not give consent
  • Patients with ASA 4 and above
  • Those with serious respiratory comorbidities (interstitial lung disease, serious permanent lung diseases)
  • Uncontrolled Hypertension, Diabetes Mellitus
  • Under 18 and over 65 years of age
  • Chronic renal failure, Liver failure
  • CHF (EF\<30) will not be included in the study

About Istanbul University

Istanbul University, a leading institution in Turkey, is dedicated to advancing healthcare through rigorous clinical research and education. Renowned for its commitment to scientific excellence and innovation, the university sponsors clinical trials that aim to enhance medical knowledge and improve patient outcomes. With a diverse team of researchers and healthcare professionals, Istanbul University fosters collaboration across disciplines to explore new therapeutic interventions and contribute to global health advancements. Its robust infrastructure and ethical standards ensure the highest quality in clinical trial management, making it a key player in the field of medical research.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported